POM-V Prescription Required

Strangvac Suspension for Injection for Horses

Active ingredient: Streptococcus equi

Form

Injection

Species

Horses

Manufacturer

Intervacc AB

VMD MA No.

EU/2/21/274/001

What it's used for

Active immunisation of horses and ponies from 5 months of age for: - Reduction of body temperature increase, coughing, inappetence, difficulty swallowing,...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Streptococcus equi

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Strangvac Suspension for Injection for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Active immunisation of horses and ponies from 5 months of age for:
- Reduction of body temperature increase, coughing, inappetence, difficulty
swallowing, and changes in demeanour in the acute stage of infection with
Streptococcus equi.

Revised: January 2025
AN: 03032/2023
- Reduction of number of abscesses within submandibular and retropharyngeal
lymph nodes.
Onset of immunity: 2 weeks after the second vaccination dose.
Duration of immunity: 2 months after the second vaccination dose.

Intramuscular use.
Shake the vial well before use. Avoid multiple vial broaching. Avoid introduction of
contamination.
It is recommended that all horses and ponies in a stable are vaccinated.
Vaccination schedule:
Primary vaccination course:
Administer one dose (2 ml) by intramuscular injection, followed by a second dose (2
ml) four weeks later.
Revaccination:
In horses at high risk of
vaccination regimen after two months.

None.

A transient increase in body temperature of up to 2.6 °C for one to five days is very
common following vaccination.
Ocular discharge which may be mucopurulent and present from both eyes is very
commonly seen for one to five days after vaccination.
Transient local tissue reactions at the injection site, characterised by heat, pain and
swelling (approximately 5 cm diameter) are very commonly seen and last for up to
five days. Frequency of injection site reactions are more pronounced after the second
primary dose and further doses. Injection site swellings exceeding 8 cm are
uncommonly seen; the majority of these have been observed in the pectoral muscle.
Muscle stiffness around the injection site occurs uncommonly.
Loss of appetite and demeanour changes for one day are common.
Anaphylactic-like reactions occur in very rare cases.

Revised: January 2025
AN: 03032/2023
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Vaccinate healthy animals only.
Effect of vaccination on further stages of the infection, rupture of developed lymph
node abscesses, prevalence of subsequent carrier status, bastard strangles
(metastatic abscessation), purpura haemorrhagica and myositis and recovery, is not
known.
Efficacy has been demonstrated for the individual horse to reduce clinical signs of
disease in the acute stage of the infection. Vaccinated horses can be infected and
shed S. equi

Special precautions for use in animals
No information is available on the use of the vaccine in seropositive animals,
including those with maternally derived antibodies.
Biosecurity procedures to limit the risk of introduction and spread of
in premises should be part of management tools.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician. An allergic reaction may occur. Treat
symptomatically. Strangvac contains saponins, which have little toxicity for humans
when ingested but have haemolytic effects when injected intravenously.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.

Store and transport refrigerated (2 C – 8 C).
Do not freeze.
Keep the vial in the outer carton in order to protect from light.

Zero days.

Revised: January 2025
AN: 03032/2023
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: immunologicals for Equidae
vaccines for horses.
ATCvet code: QI05AB01 – streptococcus.
The vaccine contains recombinant protein antigens derived from Streptococcus equi,
which are not living and cannot spread to other animals. Strangvac stimulates active
immunity against Streptococcus equi, the causative agent of strangles in horses.
After vaccination, in addition to antibodies in the blood, local antibodies (IgG) can
also be detected in secretions from the nasal passages. The immunogenicity of the
Streptococcus equi antigens is enhanced by ISCOM (Immune Stimulating COMplex).
Based on measured antibody titers immunological memory response was found in
horses following repeated vaccination 6 months after primary vaccination. The role of
the measured antibodies in the immune response relevant for the protection against
strangles is not known.
Strangvac does not contain the DNA targets of diagnostic qPCR tests for
Streptococcus equi or the A and C antigens used in the iELISA diagnostic test for
exposure to .

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.